Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy such as doxorubicin use different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of doxorubicin by making tumor cells more sensitive to the drug.

PURPOSE: Phase II trial to study the effectiveness of combining oblimersen with doxorubicin in treating patients who have locally advanced, recurrent, or metastatic hepatocellular carcinoma (liver cancer).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Princess Margaret Hospital, Canada; University Health Network, Toronto
• Collaborator: National Cancer Institute (NCI)
• Treatments: Doxorubicin; Liposomal doxorubicin; Oblimersen

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of 1 of the following:

• Histologically or cytologically confirmed hepatocellular carcinoma (HCC)

• Locally advanced, recurrent, or metastatic

• Not candidates for surgical/radical therapies

• Other solid tumor that is incurable (closed to accrual as of 11/7/03)

• At least 1 unidimensionally measurable lesion

• At least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan

• Target lesion may not be in a previously irradiated field unless subsequent progression was documented

• No ascites

• No known brain metastases

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• ECOG 0-2 OR

• Karnofsky 60-100%

Life expectancy

• More than 3 months

Hematopoietic

• WBC at least 2,000/mm^3

• Absolute neutrophil count at least 1,500/mm^3

• Platelet count at least 100,000/mm^3

Hepatic

• Bilirubin no greater than 2.0 mg/dL

• AST no greater than 5 times upper limit of normal (ULN)

• Albumin greater than 3.5 g/dL

• No cirrhosis worse than Childs-Pugh class A

Renal

• Creatinine no greater than 1.25 times ULN OR

• Creatinine clearance at least 50 mL/min

Cardiovascular

• LVEF normal by MUGA

• No symptomatic congestive heart failure

• No unstable angina pectoris

• No cardiac arrhythmia

Other

• Good nutritional status

• No encephalopathy

• No other concurrent uncontrolled illness

• No ongoing or active infection

• No psychiatric illness or social situation that would preclude study participation

• No prior allergic reactions to compounds of similar chemical or biological composition to oblimersen or doxorubicin

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy

• No more than 1 prior biologic therapy regimen for patients with HCC

• At least 4 weeks since prior biologic therapy

Chemotherapy

• Patients with HCC:

• No prior systemic chemotherapy

• Prior chemotherapy as part of localized chemoembolization therapy may be allowed (no more than 150 mg/m^2 for doxorubicin) if completed at least 8 weeks before study treatment

• All other patients (closed to accrual as of 11/7/03):

• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)

• No prior doxorubicin, epirubicin, or other anthracycline

Endocrine therapy

• Not specified

Radiotherapy

• See Disease Characteristics

• At least 4 weeks since prior radiotherapy

• No more than 3,000 cGy to fields including substantial bone marrow

Surgery

• At least 8 weeks since prior surgery

• Prior liver transplant for HCC allowed

Other

• Recovered from all prior therapy

• At least 8 weeks since other locally ablative therapies

• No concurrent commercial or other investigational agents or therapies

• No other concurrent anticancer therapy

• No concurrent combination antiretroviral therapy for HIV-positive patients